Market Overview

Express Scripts Margins Could Face Downward Pressure From Less Prescription Growth

Share:
Express Scripts Margins Could Face Downward Pressure From Less Prescription Growth

Argus' David Toung reiterated Express Scripts Holding Company (NASDAQ: ESRX)'s Hold rating after forecasting slow prescription growth for the company.

The analyst acknowledged the company's hike on 2016 EPS guidance, but noted the increase was mainly driven by a lower share count rather than a stronger earnings outlet. Despite Toung raising his FY17 EPS estimate from $6.32 to $6.38, the analyst expects heightened competition from other large prescriptions under management.

In addition to competition, Express Scripts' legal dispute with Anthem Inc (NYSE: ANTM) has created a "cloud over the stock" according to Toung.

Mixed Retention Rate

"The company raised its guidance for client retention slightly when it announced 2Q16 results on July 26. It now expects to retain 96–98 percent of the business up for renewal at the end of 2016, up from a prior view of 95–97 percent," stated Toung. The updated forecast, however didn't include Express Scripts' "rolloff of a contract" with Coventry, ending this year.

Related Link: Write A Prescription For More Pharma M&A With This ETF

"To be sure, as Express's retention rate has improved, so have trends in prescription volume. ESRX management now projects 1.260—1.290 million adjusted prescription claims this year, down 1.8 percent at the midpoint of the range from 2015. This is a shallower decline than the 11.4 percent drop in prescription volume sustained in 2014, as Express lost accounts due to the departure of account managers during the integration of Medco and Express Scripts and the merger of certain insurance plans."

Overall, the analyst forecast slower-than-usual prescription growth for the company based on management's estimates.

According to TipRanks, David Toung has a 70 percent success rating and a +11.5 percent average return per recommendation.

At time of writing, Express Scripts was flat on the day.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for ESRX

DateFirmActionFromTo
Nov 2018MaintainsMarket PerformMarket Perform
Nov 2018MaintainsEqual-WeightEqual-Weight
Sep 2018DowngradesOutperformNeutral

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Guidance Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (ESRX + ANTM)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.

Latest Ratings

StockFirmActionPT
IINDoughertyAssumes34.0
PNRJefferiesInitiates Coverage On
YYUBSUpgrades
ROKUOppenheimerMaintains155.0
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cocoa Futures Move Down

Technical Alert: Crude Give Backs Tuesday's Ill-Gotten Gains